X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs NOVARTIS - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA NOVARTIS SUN PHARMA/
NOVARTIS
 
P/E (TTM) x 28.4 397.4 7.2% View Chart
P/BV x 3.0 31.8 9.4% View Chart
Dividend Yield % 0.4 1.4 29.3%  

Financials

 SUN PHARMA   NOVARTIS
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
NOVARTIS
Mar-18
SUN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs701758 92.4%   
Low Rs433579 74.8%   
Sales per share (Unadj.) Rs110.4228.4 48.3%  
Earnings per share (Unadj.) Rs11.031.7 34.6%  
Cash flow per share (Unadj.) Rs17.232.8 52.6%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.41.5 23.6%  
Book value per share (Unadj.) Rs158.8297.1 53.4%  
Shares outstanding (eoy) m2,399.2624.69 9,717.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.9 175.4%   
Avg P/E ratio x51.621.1 245.2%  
P/CF ratio (eoy) x32.920.4 161.2%  
Price / Book Value ratio x3.62.2 158.7%  
Dividend payout %18.231.5 57.8%   
Avg Mkt Cap Rs m1,360,02116,505 8,239.9%   
No. of employees `00017.80.7 2,663.0%   
Total wages/salary Rs m53,6711,445 3,713.5%   
Avg. sales/employee Rs Th14,890.98,441.3 176.4%   
Avg. wages/employee Rs Th3,017.12,163.6 139.4%   
Avg. net profit/employee Rs Th1,480.61,173.1 126.2%   
INCOME DATA
Net Sales Rs m264,8955,639 4,697.7%  
Other income Rs m8,3881,718 488.1%   
Total revenues Rs m273,2827,357 3,714.5%   
Gross profit Rs m56,081-63 -89,730.1%  
Depreciation Rs m14,99825 59,282.2%   
Interest Rs m5,17655 9,359.3%   
Profit before tax Rs m44,2951,575 2,812.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452792 1,067.7%   
Profit after tax Rs m26,338784 3,361.1%  
Gross profit margin %21.2-1.1 -1,910.1%  
Effective tax rate %19.150.3 38.0%   
Net profit margin %9.913.9 71.5%  
BALANCE SHEET DATA
Current assets Rs m316,3599,522 3,322.6%   
Current liabilities Rs m198,6433,296 6,026.8%   
Net working cap to sales %44.4110.4 40.3%  
Current ratio x1.62.9 55.1%  
Inventory Days Days9537 259.0%  
Debtors Days Days10828 378.9%  
Net fixed assets Rs m213,17846 463,430.7%   
Share capital Rs m2,399123 1,944.3%   
"Free" reserves Rs m378,6067,213 5,248.9%   
Net worth Rs m381,0067,336 5,193.4%   
Long term debt Rs m17,7210-   
Total assets Rs m643,02811,105 5,790.3%  
Interest coverage x9.629.5 32.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.5 81.1%   
Return on assets %4.97.6 64.9%  
Return on equity %6.910.7 64.7%  
Return on capital %10.022.2 45.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81661 67,353.8%   
Fx outflow Rs m30,1433,630 830.4%   
Net fx Rs m10,673-3,570 -299.0%   
CASH FLOW
From Operations Rs m39,0721,610 2,427.0%  
From Investments Rs m-33,708687 -4,906.6%  
From Financial Activity Rs m-15,393-2,677 575.1%  
Net Cashflow Rs m-7,359-380 1,938.6%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 2.0 256.5%  
FIIs % 23.0 1.6 1,437.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.5 38.6%  
Shareholders   133,026 41,647 319.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and IT Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector and IT sector.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Mar 20, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS